Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Jan;204(1):19-21.
doi: 10.1111/bjh.19257. Epub 2023 Dec 11.

Evidence creation for myelofibrosis: Challenges and opportunities

Vikas Gupta  1
Affiliations
Comment

Evidence creation for myelofibrosis: Challenges and opportunities

Vikas Gupta. Br J Haematol. 2024 Jan.

Abstract

Evidence-based guidelines for rare diseases, such as myelofibrosis (MF), continue to prove challenging to develop, and decision-making for MF is complex. The British Society for Haematology (BSH) has created a pragmatic symptom-guided risk-adapted framework on all aspects of management of MF and shared best practices on the use of JAK inhibitors, transplantation and other conventional therapies in the management of myelofibrosis. Commentary on: McLornan et al. The management of myelofibrosis: A British Society for Haematology Guideline. Br J Haematol 2024;204:136-150.

Keywords: JAK inhibitors; myelofibrosis; transplantation.

PubMed Disclaimer

Comment on

  • The management of myelofibrosis: A British Society for Haematology Guideline.
    McLornan DP, Psaila B, Ewing J, Innes A, Arami S, Brady J, Butt NM, Cargo C, Cross NCP, Francis S, Frewin R, Garg M, Godfrey AL, Green A, Khan A, Knapper S, Lambert J, McGregor A, McMullin MF, Nangalia J, Neelakantan P, Woodley C, Mead A, Somervaille TCP, Harrison CN; BSH Committee. McLornan DP, et al. Br J Haematol. 2024 Jan;204(1):136-150. doi: 10.1111/bjh.19186. Epub 2023 Dec 1. Br J Haematol. 2024. PMID: 38037886 No abstract available.

References

REFERENCES

    1. McLornan D, Psaila B, Ewing J, Innes A, Arami S, Brady J, et al. The management of myelofibrosis: a British Society for Haematology Guideline. Br J Haematol. 2024;204:136-150.
    1. Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus Ruxolitinib in Janus kinase inhibitor-naive patients with myelofibrosis. J Clin Oncol. 2017;35:3844-3850.
    1. Asshoff M, Petzer V, Warr MR, Haschka D, Tymoszuk P, Demetz E, et al. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood. 2017;129:1823-1830.
    1. England JT, McNamara CJ, Kennedy JA, Capo-Chichi JM, Huang J, Arruda A, et al. Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort. Leukemia. 2022;36:1689-1692.
    1. Lim W, Arnold DM, Bachanova V, Haspel RL, Rosovsky RP, Shustov AR, et al. Evidence-based guidelines-an introduction. Hematology. 2008;2008:26-30.

MeSH terms

Substances

LinkOut - more resources